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doi:10.1016/j.pedneo.2011.06.005Background: Cardiac troponin I (cTnI) is a very specific and sensitive marker of myocardial
injury. The degree of myocardial injury associated with transcatheter atrial septal defect
(ASD) closure in children is unknown.
Methods: In a longitudinal study on children with ASD, cTnI serum concentrations were
measured after transcatheter ASD closure. Implantation success, complications, and latest
patient follow-up were described.
Results: We inserted 73 Amplatzer septal occluders in 73 patients. Of these, we excluded two
patients in whom the device embolized to the right ventricle the day after deployment. The
median age was 4.5 years (range, 1.1e18.0) with 20 boys and 51 girls (male:female ratio,
1:2.6). The mean ASD size was 17 7 mm, and device size ranged from 7 mm to 38 mm. The
Amplatzer size/body surface area ratio was validated by demonstrating positive correlation
with cTnI elevation. In children who had a successful attempt, 30 samples had a cTnI value
higher than 1.0 mg/L l at 6 hours after procedure. Six patients had a significant release of cTnI
greater than normal limits (mean level of 1.51 0.26 mg/L).Hematology and Oncology, Department of Pediatrics, Chang Gung Children’s Hospital, Chang Gung
n, Taoyuan 333, Taiwan.
g.tw (T.-H. Jaing).
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268 H.-T. Chung et alConclusion: In our study, transcatheter ASD closure induced minor myocardial lesion, the
extent of which depended on the ratio of the occluder size to body surface area (p< 0.05)
but not on the patient’s weight or preprocedural left ventricular ejection fraction.
Copyright ª 2011, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The Amplatzer septal occluder (ASO) (AGA Medical, Ply-
mouth, MN, USA) has been proved to be a safe system for the
occlusion of secundumatrial septal defect (ASD), and its high
success rate has led to itswidespread use. Interventional ASD
occlusion produces much lower myocardial damage than
does surgical ASD closure. However, little is known about
myocardial lesions after occluder implantation in patients,
especially the relationship between occluder size and the
patient’s age, body weight, and body surface area (BSA).
Cardiac troponin I (cTnI) is a sensitive and specific
marker for myocardial damage.1e3 When compared with
adult studies, pediatric patients seem to be at a higher risk
for myocardial injury from interventional cardiac cathe-
terization.4 Catheter manipulation can also result in usually
transient but sometimes permanent damage to valvular
apparatus or to the conduction of the right or left bundle
branches because of mechanical trauma. cTnI increase is
generally used for the diagnosis of myocardial infarction,
and its concentration is increased after cardiac surgery.
The aim of this study was to evaluate the feasibility and
efficacy of percutaneous ASD closure in young children.
2. Materials and Methods
2.1. Study population
Between October 2004 and November 2008, ASD closure
with the ASO (AGA Medical, Plymouth, MN, USA) was
attempted in 73 children at our institution. Of these, we
excluded two patients in whom the device embolized to the
right ventricle the day after deployment. Seventy-one
patients were included in a prospective protocol of ASD
transcatheter closure. The median age was 4.5 years
(range, 1.1e18.0), with 20 boys and 51 girls (male:female
ratio, 1:2.6). Each patient had to have a parent or legal
guardian capable of giving informed consent in accordance
with the Helsinki Declaration.
2.2. Device
A sizing balloon catheter was introduced over an extra-stiff
guide wire positioned in the left upper pulmonary vein to
measure the balloon-stretched diameter. Interatrial
communications were assessed by transesophageal echo-
cardiography (TEE) with reference to size, position in the
interatrial septum, proximity to surrounding structures,
and adequacy of septal rim. The device was delivered
through an 8e12F kink-resistant Teflon long delivery
sheath.2.3. Technique
In all patients, implantation of an ASO was carried out
under general anesthesia. Heparin (50 mg/kg) was used as
an anticoagulant for surgical procedures, and the operation
usually required 45e90 minutes. All of them followed
a common protocol designed by Amplatz. Detailed assess-
ment of the size and morphology of the ASD was performed
by TEE with a multiplanar probe. The ASD was sized with
a sizing balloon catheter and a precalibrated sizing
template. The stretched diameter of the ASD was defined
as the diameter of a balloon that could be withdrawn across
the ASD with mild resistance and slight deformity.
Both fluoroscopy and TEE guidance were used throughout
the sizing procedure to verify proper positioning of the sizing
balloon catheter. Device selection was based on and
matched to the stretched diameter of the ASD. The selected
ASD device was 1 mm or 2 mm larger than the stretched
diameter. The selected ASO device was attached to the
delivery wire by the screw mechanism and was loaded by
withdrawal into the loader by traction on the delivery wire.
Once the devicewas successfully deployed across the ASD,
its position and stability were assessed by fluoroscopy and
TEE. Its position was deemed optimal if the device was stable
and did not obstruct the right pulmonary veins, coronary
sinus, caval veins, or the mitral valve. Any residual shunt was
documented using color flow Doppler on TEE. The ASO device
was then releasedby rotatinganticlockwise thedeliverywire.
2.4. Sampling and assays
The cTnI levels were measured with the Architect STAT
Troponin I assay (Abbott Diagnostic Division, Abbott Park,
IL, USA). The assay has a minimum detectable concentra-
tion of <0.01 mg/L, and the cutoff level (the 99th percentile
value of a reference population) for positivity is 0.032 mg/
L.5 The area under the curve (AUC), representative of the
total release of cTnI in 1 mL (cTnI-AUC) was calculated.6
CTnI concentrations were measured in serial venous blood
samples at three time intervals: before, immediately after
the intervention, and 6 hours later. If the cTnI level is
higher than 1.0 mg/L, another blood sample is taken every
6 hours until the cTnI level is less than 0.2 mg/L.
To identify cTnI rise after ASD closure and to determine
its prognostic significance, we correlated the overall cTnI
release with the patient’s age, body weight, BSA, dimen-
sions of the device, and ratio of device diameter to BSA.
The procedure time and the number of attempts of
deployment were not amenable to intervention. The study
was approved by the local research ethics committee.
Written informed consent had to be obtained from parents
or the legal guardian before each medical intervention.
Table 1 Clinical characteristics of the patients according
to the values of cTnI at 12 hours after percutaneous atrial
septal defect closure.
Variable cTnI< 0.4 mg/L
(nZ 21)
cTnI 0.4 mg/L
(nZ 50)
p
Age (y) 8.81 5.55 5.88 4.68 0.026
Sex
Male 7 (35.0) 13 (65.0) 0.531
Female 14 (27.5) 37 (72.5) 0.531
Body height (cm) 125.93 28.87 107.22 20.33 0.019
Body weight (kg) 30.77 17.83 23.18 17.50 0.102
BSA (m2) 0.97 0.40 0.79 0.37 0.086
Preprocedural LVEF 75.52 5.32 74.34 5.53 0.408
Amplatzer size 14.24 6.09 18.26 7.18 0.028
Amplatzer size/BSA 17.29 12.47 24.91 8.28 0.003a
Data are presented as n (%) or mean standard deviation.
a Statistically significant associations after multivariate
logistic regression analysis.
BSAZ body surface area; cTnIZ cardiac troponin I; LVEFZ left
ventricular ejection fraction.
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Figure 1 Correlation of myocardial damage with the ratio of
the occluder size to BSA. Overall cardiac troponin I release
after myocardial damage by interventional atrial septal defect
closure is shown versus the ratio of the occluder size to BSA.
Linear regression: RZ 0.276, pZ 0.02. Each point represents
data of an individual patient. BSAZ body surface area.
Transcatheter atrial septal defect closure 269We divided the patients into two groups. The first group
had serum cTnI levels <0.4 mg/L from the time of defect
closure to latest follow-up, whereas the second group, with
cTnI levels greater than the reference level (0.4 mg/L),
were assessed for evidence of subclinical myocardial injury
at baseline using serial echocardiography and followed for 6
months. The increase in cTnI >0.4 mg/L was chosen arbi-
trarily as a cutoff for myocardial injury before all collection
of data.7,8 All data were then compared between these two
groups.
2.5. Statistics
Data were expressed as mean standard deviation as
appropriate, whereas Chi-square tests were used for cate-
gorical variables. Independent two-sample t test was used
to test the difference between groups. Pearson’s correla-
tion coefficient was used to determine the degree of
correlation of myocardial damage with the ratio of the
occluder size to BSA. Tests of whether coefficients differed
significantly from zero were conducted at the 5% signifi-
cance level (two tailed). All the statistical analyses were
performed using SPSS version 16.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
3. Results
None of the patients had cTnI elevation before the proce-
dure, but 52 of the patients had cTnI elevation greater than
the WHO criterion for myocardial cell damage (>0.4 mg/L)
within 12 hours after the procedure.9
3.1. Implantation success
Wereportedour experienceusing theASO for defects ranging
from 7 mm to 38 mm in 73 patients. The mean ASD size was
17 7 mm, and transcatheter closure was successful in 71 of
72 patients (97.3%). However, six patients had a significant
release of cTnI greater than the normal limits (mean level of
1.51 0.26 mg/L), and peak serum levels of cTnI were
reachedwithin 6 hours after the procedure. AhighAmplatzer
size/BSA ratio is thought to be one of the contributing factors
for elevated cTnI. Significant ST-T elevation (>0.1 mV in
peripheral leads)was not observed on electrocardiogram. No
renal function impairment was noted in these patients.
The clinical characteristics of the patients when divided
into two groups according to the threshold value of cTnI are
presented in Table 1. Univariate analysis showed age, body
height, Amplatzer size, and Amplatzer size/BSA ratio to be
contributing factors for elevated cTnI. Multivariate logistic
regression analysis showed that age, body height, and
Amplatzer size did not independently predict the elevated
cTnI levels. The only significant contributory factor was the
Amplatzer size/BSA ratio. The correlation between the
Amplatzer size/BSA ratio and the degree of myocardial
injury detected by cTnI is shown in Figure 1.
3.2. Complications and follow-up
Two patients had a device embolized into the right
ventricle (surgical removal and closure of the ASD). Therewere no cases of suspected or proven device erosion. In one
patient, atrial premature contractions (APCs) were noted
1 week after the procedure and resolved after 3 weeks of
corticosteroid treatment. The size of ASO device implanted
was 38 mm, but the postoperative cTnI level was not
impressively elevated 4 hours after the procedure
270 H.-T. Chung et al(0.577 mg/L). Local irritation of the conducting system
caused by device compression was strongly suspected,
which consequently might induce APC. Corticosteroids
were used to reduce inflammation and swelling. Complete
occlusion occurred in all patients during the follow-up
period.4. Discussion
After the initial report of successful nonsurgical trans-
catheter closure of ASD,10 various devices for transcatheter
closure of ASD were introduced and are currently being
evaluated. It is well known that cardiac surgery leads to
a transient increase in cTnI serum concentration.11 Inter-
ventional ASD occlusion produces much lower myocardial
damage than does surgical ASD closure.12 High implantation
and closure rates using transcatheter ASO in children avoid
the need for cardiac surgery.13 However, a temporary rise
of the cTnI concentration was also observed after occluder
implantation, and this increase was more pronounced in
children than adults.14 After interventional ASD occlusion,
increased cTnI levels for several hours indicate some tran-
sient, reversible myocardial membrane instability because
of the device.15 Most pediatric interventional catheteriza-
tion procedures are associated with myocardial damage as
detected by cTnI elevation. Conversely, most diagnostic
procedures are associated with no detectable myocardial
injury.4 Furthermore, the patients with APCs after ASD
occlusion, which are closely associated with an inflamma-
tory focus, may respond to large doses of corticosteroids.16
CTnI is a very specific and sensitive marker of myocardial
injury.17,18 A significant increase of cTnI levels after ASD
closure has been reported.10 Some reports suggest that the
child’s myocardium is more susceptible to trauma than that
of adults, based on higher cTnI-AUC after surgery at
a younger age.6 Our results show an increase in myocardial
injury with the size of the Amplatzer device. Its size, in
turn, is defined by the ratio of the occluder size to BSA. In
our study, the intraoperative TEE showed mere nonspecific
findings.
Transcatheter closure of ASD has become a substantial
alternative to surgical therapy with regard to economic
costs, medical outcome, avoidance of unnecessary blood
transfusions, and prevention of the complications of
extracorporal circulation.2,19 Even in pediatric patients,
there is some evidence that bypass surgery could be related
to a worse neuropsychological outcome in the follow-up.20
In our study, transcatheter ASD closure was considered
safer than surgical closure. Transcatheter closure of ASD
may result in reversible myocardial damage, the extent of
which depends on the ratio of the occluder size to BSA but
is irrespective of the patient’s body weight. In fact, the
absence of skin scars, a shortening of the hospital stay, and
avoidance of admission to the intensive care unit are more
appreciated by patients and parents.
In experienced hands and highly specialized centers,
transcatheter ASD closure provides excellent results and
fewer complications, and the patients spend a shorter time
in hospital. Obtaining the measurements of cTnI in the peri-
or postprocedural period seems to be of clinical significance
in identifying high-risk patients. More studies are needed tofurther clarify the exact role of postprocedural troponin
measurement in cardiovascular risk prediction.References
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